Chardan Capital maintains Rocket Pharmaceuticals Buy, $11 target
Chardan Capital maintained Rocket Pharmaceuticals at Buy, keeping its $11.00/share price target, according to TradingView News via Benzinga ratings actions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.